Lupin Signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex in Canada

Global pharma major Lupin Limited has signed a licence and supply agreement with Spektus Pharma to commercialize the novel antidepressant DeslaFlex™ in Canada. DeslaFlex™ is an innovative antidepressant formulation developed by Spektus using the proprietary Flexitab™ oral drug-delivery platform. This strategic partnership aims to expand Lupin’s CNS portfolio and provide unique treatment options for the management of Major Depressive Disorder. The collaboration further strengthens Lupin’s CNS portfolio with physician-endorsed, value-added therapies, well aligned with a supportive regulatory environment. Lupin’s strong commercial footprint in Canada and Spektus’s capabilities in developing differentiated, novel formulations will help successfully introduce DeslaFlex™ and establish a robust platform for future launches.